REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 212 filers reported holding REATA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $2,241,296 | +51.1% | 58,997 | 0.0% | 0.11% | +32.1% |
| Q3 2022 | $1,483,000 | -17.3% | 58,997 | 0.0% | 0.08% | -35.4% |
| Q2 2022 | $1,793,000 | -7.2% | 58,997 | 0.0% | 0.13% | +54.8% |
| Q1 2022 | $1,933,000 | -82.0% | 58,997 | -85.5% | 0.08% | -78.4% |
| Q4 2021 | $10,713,000 | -84.7% | 406,264 | -41.5% | 0.39% | -82.9% |
| Q3 2021 | $69,927,000 | -22.5% | 695,033 | +9.1% | 2.27% | +1.6% |
| Q2 2021 | $90,203,000 | +20.6% | 637,344 | -15.0% | 2.23% | +35.4% |
| Q1 2021 | $74,765,000 | -19.3% | 749,897 | 0.0% | 1.65% | -33.9% |
| Q4 2020 | $92,702,000 | +75.0% | 749,897 | +37.9% | 2.50% | +62.4% |
| Q3 2020 | $52,987,000 | -36.3% | 543,901 | +2.1% | 1.54% | -39.5% |
| Q2 2020 | $83,140,000 | +8.3% | 532,878 | +0.2% | 2.54% | -18.3% |
| Q1 2020 | $76,771,000 | -12.0% | 531,878 | +24.6% | 3.11% | +21.7% |
| Q4 2019 | $87,234,000 | +527.0% | 426,719 | +146.3% | 2.56% | +372.6% |
| Q3 2019 | $13,913,000 | – | 173,285 | – | 0.54% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |